K.D.K.D.RainsfordK.D.K.D. i inni, Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases, „Inflammopharmacology”, 23 (5), 2015, s. 231–269, DOI: 10.1007/s10787-015-0239-y, PMID: 26246395.
AlbertoA.FlorisAlbertoA. i inni, Protective Effects of Hydroxychloroquine against Accelerated Atherosclerosis in Systemic Lupus Erythematosus, „Mediators of Inflammation”, 2018, DOI: 10.1155/2018/3424136, PMID: 29670462, PMCID: PMC5835241, art. ID: 3424136.
Gary P.G.P.WormserGary P.G.P. i inni, The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America, „Clinical Infectious Diseases”, 43 (9), 2006, s. 1089–1134, DOI: 10.1086/508667, PMID: 17029130(ang.).
PhilippeP.GautretPhilippeP. i inni, Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, „International Journal of Antimicrobial Agents”, 56 (1), 2020, art. nr 105949, DOI: 10.1016/j.ijantimicag.2020.105949, PMID: 32205204, PMCID: PMC7102549 [dostęp 2022-03-18](ang.).
Mandeep R.M.R.MehraMandeep R.M.R. i inni, Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis, „The Lancet”, 2020, S0140673620311806, DOI: 10.1016/S0140-6736(20)31180-6(ang.).
Mandeep R.M.R.MehraMandeep R.M.R., FrankF.RuschitzkaFrankF., Amit N.A.N.PatelAmit N.A.N., Retraction—Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis, „The Lancet”, 2020, DOI: 10.1016/S0140-6736(20)31324-6, PMID: 32485145, PMCID: PMC7260510(ang.).
T.RumschlagT.R.C.ProdromosT.RumschlagT.R., Hydroxychloroquine is effective, and consistently so when provided early, for COVID-19: a systematic review, „New Microbes and New Infections”, 38, 2020, DOI: 10.1016/j.nmni.2020.100776, PMID: 33042552, PMCID: PMC7534595(ang.).
K.D.K.D.RainsfordK.D.K.D. i inni, Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases, „Inflammopharmacology”, 23 (5), 2015, s. 231–269, DOI: 10.1007/s10787-015-0239-y, PMID: 26246395.
AlbertoA.FlorisAlbertoA. i inni, Protective Effects of Hydroxychloroquine against Accelerated Atherosclerosis in Systemic Lupus Erythematosus, „Mediators of Inflammation”, 2018, DOI: 10.1155/2018/3424136, PMID: 29670462, PMCID: PMC5835241, art. ID: 3424136.
Gary P.G.P.WormserGary P.G.P. i inni, The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America, „Clinical Infectious Diseases”, 43 (9), 2006, s. 1089–1134, DOI: 10.1086/508667, PMID: 17029130(ang.).
PhilippeP.GautretPhilippeP. i inni, Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, „International Journal of Antimicrobial Agents”, 56 (1), 2020, art. nr 105949, DOI: 10.1016/j.ijantimicag.2020.105949, PMID: 32205204, PMCID: PMC7102549 [dostęp 2022-03-18](ang.).
Mandeep R.M.R.MehraMandeep R.M.R., FrankF.RuschitzkaFrankF., Amit N.A.N.PatelAmit N.A.N., Retraction—Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis, „The Lancet”, 2020, DOI: 10.1016/S0140-6736(20)31324-6, PMID: 32485145, PMCID: PMC7260510(ang.).
T.RumschlagT.R.C.ProdromosT.RumschlagT.R., Hydroxychloroquine is effective, and consistently so when provided early, for COVID-19: a systematic review, „New Microbes and New Infections”, 38, 2020, DOI: 10.1016/j.nmni.2020.100776, PMID: 33042552, PMCID: PMC7534595(ang.).
